TELA Bio, Inc. — Form 8-K
Filed October 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
TELA Bio announced FDA 510(k) clearance on October 5, 2026 for Liora, a fully resorbable surgical mesh device for soft tissue reinforcement. Liora is the company's first fully resorbable synthetic product designed and manufactured in-house at its ISO 8 certified cleanroom in Malvern, PA. No financial impact, timeline, or commercial milestones were specified in the filing.
Why this rating
Regulatory milestone expanding product portfolio in core market; material for $76.8M company, but execution risk and revenue timing unclear.
Price action (we called it positive)
before filing · preread $1.14 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.